Now enrolling
Iovance is currently recruiting patients with different types of cancer to participate in clinical trials. Throughout the TIL treatment journey, Iovance provides individualized support for patients and physicians through IovanceCares™, a proprietary system that enables communication and coordination with healthcare providers.
Clinical trial overview
TILVANCE-301 is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced (unresectable or metastatic) melanoma.
To learn more about the trial, please call
Further details for healthcare providers can be accessed below:
Clinical trial overview
IOV-COM-202 is a Phase 2 clinical trial of Iovance TIL therapy (lifileucel, LN-145, LN-144 and LN-145-S1). It is enrolling patients who have been diagnosed with histologically confirmed unresectable or metastatic melanoma, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), recurrent or metastatic non-small cell lung cancer (NSCLC) or relapsed or refractory NSCLC.
To learn more about the trial, please call
Further details for healthcare providers can be accessed below:
Clinical trial overview
IOV-LUN-202 is a Phase 2 clinical trial of Iovance TIL therapy (LN-145), enrolling patients who have been diagnosed with histologically confirmed recurrent or metastatic NSCLC.
To learn more about the trial, please call
Further details for healthcare providers can be accessed below:
Clinical trial overview
IOV-END-201 is a Phase 2 clinical trial to evaluate the safety and efficacy of lifileucel in patients with advanced endometrial cancer.
Read about this clinical trial
To learn more about the trial, please call
Further details for healthcare providers can be accessed below:
Clinical trial overview
IOV-GM1-201 is Phase 1/2 study to evaluate the safety and efficacy of IOV-4001, a genetically modified autologous PD-1 knockout tumor-infiltrating lymphocytes (TIL) product, in patients with unresectable or metastatic melanoma, or stage III or IV non-small-cell lung cancer.
To learn more about the trial, please call
Further details for healthcare providers can be accessed below:
Clinical trial overview
IOV-CLL-01 is a Phase 1/2 study to evaluate the safety and efficacy of autologous PBL (peripheral blood lymphocytes) therapy IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
To learn more about the trial, please call:
Further details for healthcare providers can be accessed below:
This site may contain information on an investigational agent(s) or investigational uses of approved agent(s) that has not been reviewed or approved by the FDA or other regulatory authorities. Iovance does not endorse or recommend any unapproved use of its products. Please refer to product prescribing information, where available.